MorphoSys AG (MOR)
17.90
-0.08
(-0.44%)
USD |
NASDAQ |
May 07, 09:47
MorphoSys Revenue (Quarterly): 63.62M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 63.62M |
| September 30, 2023 | 69.46M |
| June 30, 2023 | 57.97M |
| March 31, 2023 | 66.93M |
| December 31, 2022 | 83.51M |
| September 30, 2022 | 96.41M |
| June 30, 2022 | 63.32M |
| March 31, 2022 | 46.53M |
| December 31, 2021 | 60.52M |
| September 30, 2021 | 48.58M |
| June 30, 2021 | 46.08M |
| March 31, 2021 | 56.86M |
| December 31, 2020 | 42.98M |
| September 30, 2020 | 25.72M |
| June 30, 2020 | 20.26M |
| March 31, 2020 | 277.24M |
| December 31, 2019 | 12.27M |
| September 30, 2019 | 13.87M |
| June 30, 2019 | 38.93M |
| March 31, 2019 | 15.39M |
| December 31, 2018 | 11.96M |
| September 30, 2018 | 63.99M |
| June 30, 2018 | 9.701M |
| March 31, 2018 | 3.438M |
| December 31, 2017 | 33.16M |
| Date | Value |
|---|---|
| September 30, 2017 | 17.69M |
| June 30, 2017 | 12.93M |
| March 31, 2017 | 12.61M |
| December 31, 2016 | 14.05M |
| September 30, 2016 | 13.91M |
| June 30, 2016 | 13.74M |
| March 31, 2016 | 13.34M |
| December 31, 2015 | 13.47M |
| September 30, 2015 | 12.56M |
| June 30, 2015 | 13.48M |
| March 31, 2015 | 79.45M |
| December 31, 2014 | 21.27M |
| September 30, 2014 | 21.73M |
| June 30, 2014 | 20.12M |
| March 31, 2014 | 21.75M |
| December 31, 2013 | 19.56M |
| September 30, 2013 | 20.36M |
| June 30, 2013 | 40.90M |
| March 31, 2013 | 22.34M |
| December 31, 2012 | 21.44M |
| September 30, 2012 | 13.79M |
| June 30, 2012 | 16.29M |
| March 31, 2012 | 15.30M |
| December 31, 2011 | -2.202M |
| September 30, 2011 | 24.17M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
12.27M
Minimum
Dec 2019
277.24M
Maximum
Mar 2020
62.69M
Average
56.86M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Incyte Corp | 880.89M |
| Novartis AG | 12.12B |
| Immatics NV | 17.15M |
| Affimed NV | 0.4448M |
| InflaRx NV | 0.0025M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 51.98M |
| Total Expenses (Quarterly) | 151.13M |
| EPS Diluted (Quarterly) | 0.3877 |
| Enterprise Value | 2.647B |
| Gross Profit Margin (Quarterly) | 75.20% |
| Profit Margin (Quarterly) | 81.70% |
| Earnings Yield | -8.40% |
| Normalized Earnings Yield | -9.398 |